Basecamp Research, a London, UK-based AI company dedicated to solving challenges in the life sciences by exploring beyond known biology, raised $60M in Series B funding.
The round was led by Singular, with additional investors including S32, redalpine, André Hoffmann, Vice-Chairman of Roche, Feike Sijbesma, Chair of Royal Philips and Former CEO of DSM, and Paul Polman, former CEO of Unilever. Returning investors participating in the Series B include True Ventures and Hummingbird Ventures.
The company intends to use the funds to scale the pace and volume of its data collection — growing its foundational dataset that already contains 100 times more advanced biological systems than the public databases most-used by pharma researchers. Building on breakthroughs such as AlphaFold-2 and making enzyme design programmable, Basecamp Research will also continue to strengthen its AI capabilities, investing in compute and working on a new generation of foundational models to tackle increasingly complex tasks.
Led by CEO Dr. Glen Gowers, Basecamp Research is building foundational AI models on ethically sourced database of biological information allowing to design complex biological systems. It collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development.
Its team of explorers, scientists and policy experts work with more than 100 biodiversity partners across the globe, delivering breakthroughs that can have a profound impact on healthcare and the lives of patients.
The Basecamp Research and the Liu Lab collaboration anticipates advancing new approaches to programmable genetic medicines that have the potential to transform treatments for a wide range of diseases.
FinSMEs
09/10/2024